Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H1 2017

Published: Mar, 2017 | Pages: 113 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H1 2017, provides an overview of the Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline landscape.

H3N2 infections are caused by variant H3N2 virus which is an influenza virus. Symptoms include cough, sore throat, runny or stuffy nose, chills, nausea, vomiting, and/or diarrhea. Risk factors include age, chronic medical conditions like asthma, diabetes, heart disease, weakened immune systems, and neurological or neurodevelopment conditions. Treatment includes antiviral medications and antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H3N2 Subtype Infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H3N2 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 7, 5, 16 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I and Preclinical stages comprises 1, 1, 1 and 4 molecules, respectively.

Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H3N2 Subtype Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H3N2 Subtype Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H3N2 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Influenza A Virus, H3N2 Subtype Infections - Overview
Influenza A Virus, H3N2 Subtype Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Influenza A Virus, H3N2 Subtype Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Influenza A Virus, H3N2 Subtype Infections - Companies Involved in Therapeutics Development
AbbVie Inc
AIMM Therapeutics BV
Aphios Corp
BiondVax Pharmaceuticals Ltd
Celltrion Inc
FluGen Inc
Glide Pharmaceutical Technologies Ltd
ILiAD Biotechnologies LLC
Inovio Pharmaceuticals Inc
Johnson & Johnson
Medicago Inc
MedImmune LLC
Mucosis BV
NanoViricides Inc
Novavax Inc
OPKO Health Inc
Protein Sciences Corp
Sanofi Pasteur SA
Sarepta Therapeutics Inc
SK Chemicals Co Ltd
Takeda Pharmaceutical Company Ltd
VBI Vaccines Inc
Visterra Inc
Zydus Cadila Healthcare Ltd
Influenza A Virus, H3N2 Subtype Infections - Drug Profiles
APP-0205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APP-309 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Aspidasept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AV-5075S - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AV-5080 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cetylpyridinium chloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CR-8020 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CR-8043 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CTP-27 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fluad (quadrivalent) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FluGEM - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gamma-Flu - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strain A/H3N2] (monovalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strain A/H3N2] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strain A/H3N2] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strain A/H3N2] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strain A/H3N2v] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strain A/H3N2v] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B/Victoria + B/Yamagata] (quadrivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata + B/Victoria] (quadrivalent, virus like particle) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, split virion) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B/Yamagata] (trivalent, virus like particle) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B] (quadrivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B] (trivalent, split virion) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + B] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-3872 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NBP-607 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NEO-8877 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NVINF-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NVINF-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides for Influenza Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pertussis [strain BPZE1] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PNSIA-28 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
radavirsen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REDEE FLU - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for RSV and Influenza A Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VIS-410 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Influenza A Virus, H3N2 Subtype Infections - Dormant Projects
Influenza A Virus, H3N2 Subtype Infections - Discontinued Products
Influenza A Virus, H3N2 Subtype Infections - Product Development Milestones
Featured News & Press Releases
Jan 12, 2017: Study Published in Vaccine Journal Indicates BiondVax's Universal Flu Vaccine Candidate May Cover Strains Which Don't Yet Exist
Jun 23, 2016: AstraZeneca provides update on Flumist Quadrivalent Vaccine in the US for the 2016-17 influenza season
Dec 21, 2012: Sarepta Therapeutics Enters Into Clinical Trial Agreement With NIH For Further Development Of Influenza Drug AVI-7100
Oct 09, 2012: NanoViricides's Oral FluCide Drug Candidate Found To Be Superior To Oseltamivir In Reduction Of Virus Load And Lung Damage Pathology In Animal Models With H3N2 Influenza
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Influenza A Virus, H3N2 Subtype Infections, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by AbbVie Inc, H1 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by AIMM Therapeutics BV, H1 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Aphios Corp, H1 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by BiondVax Pharmaceuticals Ltd, H1 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Celltrion Inc, H1 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by FluGen Inc, H1 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Glide Pharmaceutical Technologies Ltd, H1 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by ILiAD Biotechnologies LLC, H1 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Inovio Pharmaceuticals Inc, H1 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Johnson & Johnson, H1 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Medicago Inc, H1 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by MedImmune LLC, H1 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Mucosis BV, H1 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by NanoViricides Inc, H1 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Novavax Inc, H1 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by OPKO Health Inc, H1 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Protein Sciences Corp, H1 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Sanofi Pasteur SA, H1 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Sarepta Therapeutics Inc, H1 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by SK Chemicals Co Ltd, H1 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by VBI Vaccines Inc, H1 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Visterra Inc, H1 2017
Influenza A Virus, H3N2 Subtype Infections - Pipeline by Zydus Cadila Healthcare Ltd, H1 2017
Influenza A Virus, H3N2 Subtype Infections - Dormant Projects, H1 2017
Influenza A Virus, H3N2 Subtype Infections - Discontinued Products, H1 2017